High Doses of Clopidogrel to Overcome Genetic Resistance The Randomized Crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2) by Collet, Jean-Philippe et al.
A
G
S
V
P
p
R

w
t
s
i
*
A
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 4 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 3 . 0 0 2High Doses of Clopidogrel to Overcome
Genetic Resistance
The Randomized Crossover CLOVIS-2 (Clopidogrel and Response
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aris and Montpellier, France
Objectives This study sought to determine whether the pharmacokinetic (PK) and pharmacody-
namic (PD) responses to high or standard clopidogrel loading doses (LDs) differ according to
CYP2C19*2 allele.
Background CYP2C19 loss-of-function alleles are associated with reduced responsiveness to stan-
dard clopidogrel doses.
Methods Young post-myocardial infarction patients heterozygous (wild type [wt]/*2, n  43) or ho-
mozygous (*2/*2, n  8) for the CYP2C19*2 genetic variant were matched with patients not carrying
the variant (wt/wt, n  58). All patients were randomized to a 300- or 900-mg clopidogrel LD. The
relative reduction in residual platelet aggregation (RR-RPA, %) and the area under the plasma con-
centration time curve of active metabolite from baseline to 6 h after loading (AUC0-6) were com-
ared according to both LD and CYP2C19*2 carriage.
esults The 300-mg LD led to a gene-dose effect for RR-RPA (65.7%  35.9% in wt/wt vs.
48.0%  38.4% in wt/*2 vs. 14.6%  32.4% in *2/*2; overall p value  0.003, p  0.03 for
t/wt versus wt/*2, p  0.04 for wt/*2 versus *2/*2) with minor effect in *2/*2 carriers. After
he 900-mg LD, the effect of the CYP2C19*2 variant on platelet inhibition was fully compen-
ated in wt/*2 carriers but not in *2/*2 carriers (83.6%  25.8% in wt/wt vs.77.2%  26.9%
n wt/*2 vs. 29.5%  26.8% in *2/*2; overall p value  0.0003, p  0.20 for wt/wt versus wt/
2, p  0.001 for wt/*2 versus *2/*2). A similar pattern was observed for the active metabolite
UC0-6 according to carriage of CYP2C19*2 for both LDs. There was a signiﬁcant correlation be-
tween PK and PD responses irrespective of the LD.
Conclusions Carriers of CYP2C19*2 display signiﬁcantly lower responses to clopidogrel with a gene-
dose effect. Clopidogrel resistance can be overcome by increasing the dose in heterozygous carriers
but not in homozygous carriers. (Clopidogrel and Response Variability Investigation Study 2 [CLOVIS-2];
NCT00822666) (J Am Coll Cardiol Intv 2011;4:392–402) © 2011 by the American College of
Cardiology Foundation
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393Clopidogrel inhibits the P2Y12 adenosine diphosphate
ADP) receptor on platelets and has been the standard of
are in combination with aspirin to prevent cardiovascular
vents in patients with an acute coronary syndrome (ACS)
nd/or undergoing percutaneous coronary intervention
PCI). The “one size fits all” treatment strategy with
lopidogrel therapy does not take into account the large
egree of interindividual pharmacodynamic (PD) responses,
nd patients with lesser degrees of platelet inhibition and/or
igher residual platelet reactivity on clopidogrel are at
ncreased risk of cardiovascular events (1).
See page 411
Several studies have shown that higher clopidogrel loading
doses (LDs) result in higher platelet inhibition, faster onset
of action, and fewer poor responders in a dose-effect fashion
in both clopidogrel-naive and clopidogrel-treated patients
(2,3). Although some of these studies suggested that high or
very high LDs of clopidogrel afford greater clinical benefit
compared with the 300-mg LD (4,5), it is only recently that
it has been demonstrated in patients presenting with an
ACS and undergoing PCI (6).
Cytochrome P-450 (CYP) isoenzymes contribute sub-
stantially to the 2 oxidative steps necessary for the
transformation of clopidogrel into its active thiol metab-
olite (7). Carriers of reduced-function genetic variants *2 to
*8 in CYP2C19 gene—the *2 allele being the most
frequent variant (90%), found in one-third of all
comers— have lower active metabolite levels and dimin-
ished platelet inhibition (8). Carriage of even 1 reduced-
function CYP2C19 allele among coronary patients on
lopidogrel is associated with an approximately 20%
ncreased risk of cardiovascular death as compared with
oncarriers, and an approximately 3-fold increase in the
isk of stent thrombosis (9). This hazard seems to be
resent both early after initiation of clopidogrel therapy
nd later during long-term secondary prevention.
Recently, the U.S. Food and Drug Administration
FDA) issued a warning suggesting that there is diminished
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M
2ffectiveness of standard doses of clopidogrel in individuals
ith 2 reduced-function CYP2C19 alleles and that genetic
tests may be useful to identify patients at risk and to
consider alternative treatment strategies (10). The warning
only addresses patients with 2 loss-of-function alleles (*2/
*2), representing approximately 2% of Caucasians, 4% of the
black population, and up to 20% of Chinese (11). No
comment is provided for heterozygous patients (wt/*2), who
represent more than 90% of carriers and approximately
one-third of the population, although pharmacokinetic
(PK) and PD studies have
shown that even 1 reduced-
function CYP2C19 allele has a
significant impact on the re-
sponse to clopidogrel (8).
Whether increasing the dose of
clopidogrel in carriers of 1 or 2
CYP2C19 reduced-function al-
leles can improve the degree of
platelet inhibition is unknown
(12–14).
To determine whether re-
sponse to high or standard
clopidogrel LDs differs accord-
ing to the presence of 1 or 2
CYP2C19 reduced-function al-
leles, we conducted a prospective
randomized evaluation of 2
clopidogrel LDs in a gene-based
selected population of young
post-myocardial infarction (MI)
survivors.
Methods
Selection of patients. To enter
he CLOVIS-2 (Clopidogrel and
esponse Variability Investigation
tudy 2) patients were screened
rom the AFIJI (Appraisal of risk
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li Lilly, Bristol-Myers Squibb, The Medicines Company, Schering-Plough,
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Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AUC  area under the
plasma concentration time
curve
FDA  Food and Drug
Administration
HOPR  high on-treatment
platelet reactivity
LD  loading dose
LTA  light transmission
aggregometry
MD  maintenance dose
MI  myocardial infarction
MPA  maximal platelet
aggregation
PCI  percutaneous
coronary intervention
PD  pharmacodynamic
PK  pharmacokinetic
POC  point of care
PRU  platelet reaction unit
RPA  residual platelet
aggregation
RR  relative reduction
VN  VerifyNow
wt  wild typeanuscript received December 3, 2010; revised
011, accepted March 8, 2011.manuscript received February 8,
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394Factors in young Ischemic patients Justifying aggressive Inter-
vention) multicenter registry (n  566) (15). A total of 292
male patients with DNA samples were genotyped for the
CYP2C19*2 genetic variant. All homozygous and heterozygous
YP2C19*2 patients were proposed to participate in the
andomized CLOVIS-2 study. Age- and gender-matched
omozygous CYP2C19 wild-type (wt)/wt patients (noncarri-
rs) from the same AFIJI program were then recruited with a
:1 ratio for each heterozygous and a 2:1 ratio for each
omozygous patient who was willing to participate. Exclusion
riteria were any conditions requiring chronic treatment with
onsteroidal anti-inflammatory drugs or any chronic anticoag-
lant treatment.
The trial was conducted by the ACTION Academic Re-
earch Organization (Institut de Cardiologie–Pitié-Salpêtrière
ospital), sponsored by the Direction de la Recherche Clin-
que at Assistance Publique-Hôpitaux de Paris (AP-HP) and
unded by a public grant from the Programme Hospitalier de
echerche Clinique (PHRC P070117) of the French Ministry
f Health. The sponsor had no involvement in the design of
he study, data collection, analysis, or the writing of the
anuscript. The protocol was approved by the Pitié-
alpêtrière University Hospital Ethics Committee. Written
nformed consent was obtained from all patients.
Study design. All patients had survived an MI before the
ge of 45 years, were stable at the time of inclusion, and
ere all treated with a maintenance dose (MD) of 75 mg of
spirin and/or 75 mg of clopidogrel for at least 3 months.
hey were randomly assigned (web-centralized randomiza-
ion procedure) to an open-label LD of 300 or 900 mg of
lopidogrel in a 2-period crossover fashion (Fig. 1). All
nvestigations and blood sample timings were identical in
he 2 phases of the study. Briefly, patients received an initial
oad of either 300 or 900 mg according to randomization.
Figure 1. The CLOVIS-2 Study Design
PD  pharmacodynamic; PK  pharmacokinetic.lood was drawn for PD evaluations at baseline beforeoading and 6 h after drug loading. Blood samples were also
ollected for PK analyses at baseline, 1, 2, 4, and 6 h
ost-loading. A clopidogrel 75-mg MD was continued at
east 21 days before patients were crossed over to the
lternate LD of clopidogrel, and the same measurements
ere performed again.
Laboratory methods. GENOTYPING. Genomic DNA was
extracted from peripheral blood and was genotyped using
TaqMan Validated SNP assays (C_25986767_70) with the
7900HT sequence Detection System (Applied Biosystems,
Courtaboeuf, France). All patients were also genotyped for
other loss-of-function CYP2C19 variants (*3, *4, *5, *6)
using the same method (TaqMan Validated SNP assays:
C_27861809_10; C_30634136_10; C_27861810_10; and
C_27531918_10, respectively).
PD EVALUATION. Platelet measurements were performed
immediately after venipuncture in a single laboratory
blinded to the assigned LD regimen and to the genetic
profile of the study patients. Light transmission aggregom-
etry (LTA) (Model 490-4D, Chrono-Log Corporation,
Kordia, the Netherlands) and the point-of-care assay
(POC) VerifyNow P2Y12 (VN-P2Y12) assay (Accumetrics,
an Diego, California) were both used simultaneously at
aseline (before the LD) and 6 h after the LD during both
hases. Residual platelet aggregation (RPA), which corre-
ponded to the level of aggregation curve (%) measured 6
in after 20 mol/l ADP-induced platelet aggregation, was
elected because it is thought to better reflect P2Y12
function than other measurements (16). The relative reduc-
tion (RR) in RPA (RR-RPA, %) 6 h post-LD was defined
as (% RPA6 h)  (% RPAbaseline)/(% RPAbaseline)  100.
Pre-specified criteria to define nonevaluable samples were
the lack of sufficient signal, hemolysis, PRP platelet count
150,000/l, and unstable baseline.
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395For the VN-P2Y12 assay, samples were run in the same
aboratory, according to the device package insert. Platelet
eaction units (PRU) were reported and correlated to RPA
t each time point.
MEASURE OF PLASMA CONCENTRATION OF ACTIVE METABO-
LITE. Whole blood was immediately stabilized with 500
mM MPBr (3-methoxyphenacyl bromide) and processed to
obtain platelet-poor plasma aliquots, and then stored at
80°C. Plasma concentration of active metabolite isomers
stabilized as 3=methoxyacetophenone derivates was de-
termined by a validated electrospray liquid chromatogra-
phy tandem mass spectrometry method. Data on the
active metabolite isomer H4 were reported because iso-
mer H3 was inactive and isomers H1 and H2 were
nonquantifiable (17).
The area under the plasma concentration time curve
(AUC) from the time of administration of the LD to 6 h
(AUC0-6) of active metabolite was computed by noncom-
partmental methods of analysis with the use of the log-
linear trapezoidal method (Phoenix WinNonlin, version
6.0, Pharsight, St. Louis, Missouri).
Endpoints. The primary aim was to evaluate RR-RPA
fter 300- and 900-mg clopidogrel LDs according to the
YP2C19*2 genotype.
Other endpoints were the rate of high on-treatment
latelet reactivity (HOPR) according to established cutoff
alues for both methods (64.5% for 20 M ADP, 236 PRU
for VN-P2Y12 assay) (1), the relative reduction in platelet
ggregation expressed as P2Y12 PRU (RR-PRU) measured
with the VN-P2Y12 assay according to CYP2C19*2 geno-
ype, and the correlation between RR-RPA and AUC0-6 for
oth LDs. An analysis was performed according to clopi-
ogrel pretreatment status.
Statistical analysis. The sample size was calculated to dem-
nstrate that the administration of a 300-mg LD would
roduce a 40% lower RR-RPA in carriers of CYP2C19*2 as
ompared with the effect observed in noncarriers according
o a previous difference of 50% reported in healthy volun-
eers (18). To demonstrate such a difference, the inclusion
f 45 carriers was required to yield 90% power with an
lpha-risk error of 0.05 and assuming a 20% standard
eviation for the difference between regimens.
Continuous variables were expressed as mean  SD
nless otherwise stated, and categorical variables as frequen-
ies and percentages. Baseline characteristics of patients by
enotypes were compared using the chi-square test for
ategorical variables, and Student t test or 1-way analysis of
ariance for continuous variables as appropriate. For RPA
easures, data were included for subjects with evaluable
PA measurements at baseline and 6 h in both phases. The
D response to clopidogrel was primarily defined as RR-
PA (%) to adjust for pre-treatment status with clopidogrel
D. After checking for the absence of carryover effect, theomparison between clopidogrel response across genotyperoups and the 2 LDs tested (300-mg vs. 900-mg LD) was
valuated by the Kruskall-Wallis test. Two-sided unpaired
ilcoxon test was then used to compare endpoints between
genotypes. Only patients who successfully completed the
treatment periods of the study were considered for
nalysis. A similar approach was used for the PK response
efined as AUC from the time of administration of the
D to 6 h. The clopidogrel PK/PD relationship was
valuated by nonlinear regression analysis. The best fit
as obtained with hyperbolic decay model with a baseline
f the following form: E  ab/b  AUC0-6. The effect
E) was RR-RPA obtained after 300-mg and 900-mg
Ds.
Comparisons are expressed as univariate hazard ratios and
5% confidence intervals, including the entire duration of
ollow-up. All analyses were performed with the use of SAS
oftware, version 9.1 (SAS Institute, Cary, North Carolina).
ll p values are 2 sided.
esults
Study population. A total of 43 heterozygous carriers (wt/*2)
were matched in a 1:1 ratio with 43 wt homozygous (wt/wt)
patients, and 8 (6.6%) homozygous carriers (*2/*2) were
matched in a 1:2 ratio with 16 wt homozygous (wt/wt)
patients, constituting then a population of 110 coronary pa-
tients to be randomized to 1 or the other LD of clopidogrel.
Fifty-five patients started with the 300-mg LD regimen and
55 with the 900-mg LD regimen. At the final stage, 106
completed the 2 periods of the randomized CLOVIS-2
study (58 wt/wt, 41 wt/*2, and 7 *2/*2, respectively). Four
patients were heterozygous carriers of the CYP2C19*4
variant, whereas CYP2C19*3, -*5, or -*6 was not found in
any of the patients. In the overall genotyped patients, there
was no deviation from the expected proportions of geno-
types predicted by the Hardy-Weinberg equilibrium for
polymorphisms (p  0.40).
Baseline characteristics were representative of a typical
young MI population. No statistical difference between the
randomized sequences was found, including for the baseline
value of RPA (data not shown). A total of 86 patients were
treated by a MD of clopidogrel at baseline and for at least 3
months prior to entering the study. Naive patients (n  20)
prior to randomization were not treated with a MD between
the 2 sequences. Patients had a high prevalence of familial
history of coronary artery disease. Baseline characteristics
were well balanced between the 2 groups defined by
CYP2C19*2 genotypes (Table 1).
Pharmacodynamic response to clopidogrel according to the
CYP2C19*2 genetic variant. Baseline RPA and maximal
platelet aggregation (MPA) differed significantly according
to CYP2C19*2 carriage in patients on 75-mg clopidogrel
MD (n  86) with a significant gene-dose effect (Tables 2
and 3). The lowest average RPA/MPA was observed in
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396wt/wt patients, and the highest in patients with 2 CYP2C19
reduced-function alleles (*2/*2) (Fig. 2). A similar pattern
was observed when measuring the P2Y12 PRU (Table 3).
These differences were not observed in clopidogrel-naive
patients. The effect of the LD was then assessed in the
whole population irrespective of clopidogrel pre-treatment
prior to loading (n 106). There was a stepwise decrease of
R-RPA from wt/wt to carriers, with a significant gene-
ose effect following the 300-mg LD (Fig. 3). The maximal
R-RPA was observed in wt/wt and was significantly lower
n carriers with an intermediate effect in wt/*2. Indeed,
hereas the 300-mg LD resulted in a significant reduction
n platelet aggregation in wt/wt and wt/*2 patients, there
as no detectable effect on RPA or MPA in *2/*2 carriers
RPA/MPA [%]: 65.43  11.23 and 67.27  10.60 before
s. 60.10  28.75 and 66.97  23.91 after loading,
espectively, p  ns for both measurements). The 900-mg
Table 1. Baseline Characteristics of the Patients Ac
Characteristics
Overall
(n  106)
Age, yrs 40.1 4.8
BMI, kg/m2 26.1 3.8
Race or ethnic background
White European 81.1
North African 12.3
Black 0.9
Asian 5.6
Risk factors
Familial history of CAD 38.0
Active cigarette smoking 56.9
Dyslipidemia 68.9
Arterial hypertension 28.3
Diabetes mellitus 15.1
Number of vessels
Single 60.0
Double 22.9
Triple 16.2
Revascularization
Bypass only 5.6
PCI only 88.8
Both 5.6
Multiple vascular disease* 7.5
Drug therapy during follow-up
Clopidogrel at inclusion 82.1
Aspirin 92.4
Statins 95.0
Beta-blockers 76.4
Proton pump inhibitors 44.3
Values are mean SD or %. *Defined as simultaneous presence of cli
BMI body mass index; CAD coronary artery disease; PCI percD blunted the effect of the CYP2C19*2 variant on RR- lPA in wt/*2, which did not differ from wt/wt (Fig. 3). In
ontrast, there was little effect of the 900-mg LD in *2/*2
arriers. Further statistical analyses according to CYP2C19*2
enotype confirmed that a gene-dose effect was observed
ollowing the 300-mg LD but not following the 900-mg
D (Fig. 3). This pattern was also observed when consid-
ring MPA (data not shown).
The magnitude of change in RR-RPA according to
YP2C19*2 carriage appeared to be similar in patients
reated by a MD of clopidogrel (n 86) and in clopidogrel-
aive patients (n  20) (Tables 2 and 3), and there was no
ignificant interaction of pre-treatment status and CYP2C19*2
arriage on all PD parameters. Pharmacodynamic re-
ponse evaluated by the POC VN-P2Y12 assay led to a
imilar pattern as with ADP-induced RPA (LTA) with
espect to genetic variants and LDs (Table 3). The
revalence of HOPR, defined according to LTA estab-
g to CYP2C19*2 Genotype
CYP2C19*2 Genotype
wt/wt
(n  58)
wt/*2
(n  41)
*2/*2
(n  7)
40.1 4.6 40.2 4.7 39.9 4.7
26.2 3.5 26.1 4.3 26.0 3.6
84.5 75.6 71.4
12.1 9.8 28.6
1.7 0 0
1.7 12.1 0
41.4 35.0 28.5
60.3 43.9 14.3
68.9 68.3 71.4
34.5 21.9 14.3
19.0 12.2 0
61.4 63.4 28.6
24.6 19.5 28.5
14.0 14.6 42.8
3.4 4.9 28.5
93.1 95.1 71.5
3.5 0 0
8.6 4.9 14.3
89.6 78.1 42.8
93.1 92.7 85.7
100 100 97.6
81.0 65.8 100
48.3 43.9 14.3
ymptomatic peripheral arterial disease or cerebrovascular disease.
us coronary intervention; wtwild type.cordin
nically sished cutoff values (1), increased with respect to the
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397number of reduced-function CYP2C19 alleles, although it
as blunted after administration of the 900-mg LD in
atients carrying a single allele (Table 2). HOPR was
uch less frequent according to the established cutoff of
RU (235) with no significant gene-dose effect as
bserved with LTA (Table 3). No statistically significant
ifferences were observed by sequence or period, and
here was no treatment–period interaction, suggesting no
arryover effect.
PK response. Carriers of the CYP2C19*2 variant displayed
reduced plasma concentration of the active metabolite
compared with wt/wt, with a significant gene-dose effect
after exposition to both LDs (Fig. 4). There was no
detectable difference in active metabolites levels achieved
after 300-mg LD between wt/*2 and *2/*2 (p  0.13).
Compared with the levels observed after a 300-mg LD, the
900-mg LD led to a 2-fold increase in active metabolite
concentration in wt/wt and wt/*2 patients (Fig. 4). This
concentration was also increased by 1.5-fold in *2/*2 pa-
tients. The gene-dose effect was present with both LDs but
was stronger with the 900-mg LD. Interestingly, *2/*2
carriers still displayed a reduced PK response after 900-mg
Table 2. Effect of Clopidogrel LDs on RPA as Measur
CYP2C19*2 Carriage and Clopidogrel Pretreatment
Clopidogrel Pre-Treated Patients
(n  86)
wt/wt
(n  52)
Baseline RPA* 28.1 20.4
300-mg post-loading RPA 11.8 16.5
900-mg post-loading RPA 6.5 12.1
300-mg post-loading RR-RPA† 68.0 34.8
900-mg post-loading RR-RPA† 86.5 20.9
Clopidogrel Naive Patients
(n  20)
wt/wt
(n  6)
Baseline RPA* 65.3 11.2
300-mg post-loading RPA 36.0 30.5
900-mg post-loading RPA 25.2 34.3
300-mg post-loading RR-RPA† 48.2 42.7
900-mg post-loading RR-RPA† 61.6 46.5
High On-Treatment Platelet Reactivity (MPA >64.5%)
wt/wt
At baseline* 7/52 (13.46%)
300-mg post-loading 3/58 (5.17%)
900-mg post-loading 2/58 (3.45%)
Effect on theproportionof patientswithhighon-treatmentplatelet rea
[1]) is also provided. *Baseline RPA/MPA is reported as the average of b
carriage was nonsignificant for RR-RPA obtained after both LDs (p 0
LD  loading dose; LTA  light transmission aggregometry; MPA
RR  relative reduction.LD, with similar levels to those measured after the 300-mgLD in wt/*2 carriers. There was no influence of clopidogrel
pre-treatment status (Table 4).
There was a significant and similar relationship between
active metabolite plasma concentrations (AUC0-6, in ng · h/
l) and RR-RPA following both LDs (Figs. 5A and 5B)
ith a right shift of the 900-mg LD curve. The lowest
UC0-6 (10 ng · h/ml) values were associated with a
great variability of PD, which was not observed with the
900-mg LD. The PK/PD relationship suggests that
isomer H4 metabolite AUC0-6 20 ng · h/ml is neces-
ary to obtain a meaningful inhibitory effect of clopi-
ogrel loading, although this latter remains still highly
ariable. Such levels were more likely achieved in wt/wt
atients and/or after 900-mg LD. An isomer H4 metab-
lite AUC0-650 ng · h/ml was associated with maximal
ntiplatelet effect.
iscussion
By pairing patients according to their genetic background
and by assessing simultaneously PD and PK responses after
exposure to 2 different clopidogrel doses randomly allocated,
20 mol/L ADP-Induced LTA According to Both
Carriers
p Value
wt/*2
(n  31)
*2/*2
(n  3)
39.5 23.3 59.3 16.5 0.02
22.3 20.6 47.5 35.8 0.007
13.9 18.6 37.9 32.4 0.01
47.6 40.4 26.7 37.2 0.04
75.2 28.5 37.1 41.0 0.02
Carriers
p Value
wt/*2
(n  10)
*2/*2
(n  4)
62.0 21.1 70.0 2.5 0.88
31.6 24.1 69.6 22.8 0.16
11.8 15.4 53.3 9.4 0.06
49.5 33.3 0.95 25.4 0.08
90.0 21.8 23.7 14.6 0.05
wt/*2 *2/*2
7/31 (22.6%) 1/3 (33.3%) 0.34
6/41 (14.63%) 4/7 (57.14%) 0.0017
2/41 (4.88%) 4/7 (51.14%) 0.0005
efinedas anestablished cutoff valueof 64.5% (aspreviously proposed
ases. †p for interaction between pre-treatment status and CYP2C19*2
00-mg LD; p 0.11 for 900-mg LD).
ximal platelet aggregation; RPA  residual platelet aggregation;ed by
Status
ctivity d
oth ph
.41 for 3
 mawe demonstrate that carriage of the loss-of-function
a
o
P
s
p
r
r
le 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 4 , 2 0 1 1
A P R I L 2 0 1 1 : 3 9 2 – 4 0 2
Collet et al.
The CLOVIS-2 Study
398CYP2C19*2 variant is associated with: 1) a gene-dose
response to a standard clopidogrel 300-mg LD and 75-mg
MD; and 2) a correction of the genetic trait effect by using
a higher dose of the drug, which is, however, limited to
heterozygous patients. Indeed, in wt/*2 heterozygous pa-
tients, the 900-mg LD totally compensated for the genetic
deficiency on both the active metabolite concentration and
platelet inhibition, which finally did not differ from wt/wt
patients. In contrast, *2/*2 carriers still displayed a reduced
PK/PD response with the 900-mg LD.
Recent meta-analyses have suggested that heterozygous
and homozygous carriers of the reduced-function
CYP2C19*2 allele experience diminished clinical effective-
ness of clopidogrel after PCI and/or ACS (9). Heterozygous
carriers of the CYP2C19 reduced-function allele represent
the vast majority of carriers and are at significantly higher
risk of adverse cardiovascular events as compared with wt/wt
patients. Homozygous *2/*2 carriers are also at higher risk
than wt/*2 but with overlapping confidence intervals of the
point estimates. These clinical data are now supported by
the results of our CLOVIS-2 randomized study, designed
with an enrichment strategy in which patients were selected
Table 3. Effect of Clopidogrel LDs on PD Response M
CYP2C19*2 Carriage and Clopidogrel Pretreatment
Clopidogrel Pre-Treated Patients
(n  86)
wt/wt
(n  52)
Baseline PRU* 121 73
300-mg post-loading PRU 70 64
900-mg post-loading PRU 38 47
300-mg post-loading RR-PRU† 41.67 28.65
900-mg post-loading RR-PRU† 76.02 23.69
Clopidogrel Naive Patients
(n  20)
wt/wt
(n  6)
Baseline PRU* 237 48
300-mg post-loading PRU 166 100
900-mg post-loading PRU 99 117
300-mg post-loading RR-PRU† 43.52 25.00
900-mg post-loading RR-PRU† 64.52 37.79
High On-Treatment Platelet Reactivity (PRU >235)
wt/wt
At baseline* 3/52 (5.77%)
300-mg post-loading 2/58 (3.45%)
900-mg post-loading 1/58 (1.72%)
Relative change in platelet aggregation is expressed as P2Y12 plate
treatmentplatelet reactivity definedas anestablished cutoff valueof 23
as the averageof bothphases.†p for interactionbetweenpre-treatmen
both LDs (p 0.76 for 300mg LD; p 0.62 for 900-mg LD).
POC point of care; VN VerifyNow; other abbreviations as in Tabaccording to the presence of the CYP2C19*2 genetic variant,allowing a more accurate evaluation of 1 versus 2 reduced-
function CYP2C19 alleles. Clopidogrel MDs and LDs have
n incremental PK/PD effect according to the presence of 1
r 2 CYP2C19*2 alleles. The consistent findings on PK and
D with the 75-mg MD and 2 different LDs strongly
uggest a gene-dose effect of the CYP2C19*2 variant and
ossibly a codominant effect.
CLOVIS-2 evaluated the effect of 2 different LDs in a
andomized fashion according to the presence of the
educed-function CYP2C19*2 allele. The labeled 300-mg
LD appears adequate in the majority of patients with the
wt/wt genotype but appears insufficient in carriers of at least
1 reduced-function CYP2C19*2 allele. The 900-mg LD was
chosen because it was shown to be superior to both 300 and
600 mg to reduce poor clopidogrel response, in both naive
patients and patients already taking 75 mg/day clopidogrel
(2,3). Importantly, in contrast to a previous study looking
at the effect of 600-mg LD (19), it has been demon-
strated that in the dose range of 900 mg, there was no
limitation due to intestinal absorption (2). CLOVIS-2
further demonstrates that we can overcome genetic resis-
tance to clopidogrel in heterozygous wt/*2 carriers al-
red Using the POC VN-P2Y12 Assay According to
Carriers
p Value
wt/*2
(n  31)
*2/*2
(n  3)
159 66 212 97 0.04
112 64 230 105 0.0008
74 78 187 102 0.004
35.91 27.75 12.14 16.27 0.02
61.74 31.90 16.61 4.60 0.002
Carriers
p Value
wt/*2
(n  10)
*2/*2
(n  4)
224 58 220 32 0.82
128 73 209 17 0.32
82 57 173 49 0.19
40.46 30.61 7.37 10.64 0.12
64.88 22.41 18.71 16.23 0.04
wt/*2 *2/*2
5/31 (16.13%) 1/3 (33.3%) 0.081
1/41 (2.44%) 1/7 (14.29%) 0.348
1/41 (2.44%) 1/7 (14.29%) 0.242
tion units (PRU). Effect on the proportion of patients with high on-
eviously proposed [1]) is alsoprovided. *BaselineRPA/MPA is reported
andCYP2C19*2 carriagewasnonsignificant for RR-RPAobtained aftereasu
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399Indeed, PD and PK responses in wt/*2 carriers signifi-
cantly differ from that of wt/wt patients with the standard
clopidogrel dosing regimen but are normalized with the
900-mg LD. This further extends our previous report on
a high clopidogrel MD to overcome poor responsiveness
in wt/*2 patients (12).
CLOVIS-2 also demonstrates that *2/*2 carriers re-
sponded poorly to both LDs suggesting a profile of
complete resistance to clopidogrel. This further supports
that a strategy of an increased clopidogrel-dose regimen
is ineffective, as previously reported in patients who
survived a stent thrombosis and who have both persistent
HOPR and a genetic profile of resistance (13). These
patients deserve alternative therapy and should be
switched to novel and more effective P2Y12 inhibitors
such as prasugrel, although no definitive conclusion can
be drawn, given the small number of *2/*2 patients and a
better response in pre-treated patients versus naive pa-
tients (13). Altogether, these results suggest that therapy
individualized on the genetic profile is possible with
standard treatment in homozygous wt/wt patients, in-
creased clopidogrel dosing in heterozygous wt/*2 carriers,
and new P2Y12 antagonists in homozygous *2/*2 carriers,
o reach an appropriate range of P2Y12 inhibition in all
patients. Although the evidence base for such an option
currently does not exist, these new data may help in
interpreting the recommendations recently released by
the American College of Cardiology/American Heart
Association on pharmacogenetic testing to identify pa-
tients’ altered clopidogrel metabolism (20). The
wt/wt wt/*2 *2/*2
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Figure 2. ADP-Induced RPA at Baseline According to CYP2C19*2 and
Clopidogrel 75-mg LD
Measurements are mean  SD and were obtained in the 86 patients
exposed to a maintenance (MD) of 75-mg clopidogrel who completed the
2 phases. RPA  residual platelet aggregation.CLOVIS-2 study also suggests that a study design withgenotype enrichment in a population at risk is feasible
and may represent a novel approach for evaluating
personalized medicine.
The CLOVIS-2 study shows that the association between
the presence of a reduced-function CYP allele and platelet
inhibition is primarily due to reduced plasma exposure to the
active metabolite of clopidogrel. We confirm a significant
gene-dose effect of CYP2C19*2 and a drug-dose effect in these
patients, both at the PK and PD levels. The clopidogrel active
metabolite is a mixture of 4 unstable diastereoisomers, which
remain a technical challenge to measure, especially if clopi-
dogrel is used as the reference to establish the calibration curve
(17). To avoid such limitations, concentrations of individual
stabilized isomers were determined, and the H4 isomer, the
only diastereoisomer of clinical relevance for documenting the
PK profile of clopidogrel’s active metabolite, was taken into
account using a method that was validated in compliance with
the FDA guidelines.
Our results provide new insights in the understanding of
clopidogrel metabolism. The use of a higher LD in
CYP2C19-deficient patients (i.e., *2/*2) results in an increase
in the isomer H4 active metabolite levels (from 9.94  2.88
ng · h/ml to 15.84  5.26 ng · h/ml for 300-mg and
900-mg LDs, respectively, p  0.007, see Fig. 4), suggest-
ing a CYP2C19-independent metabolic pathway that
could be linked to other cytochromes such as CYP3A4 or
CYP1A2 (7). Of interest, this increase in isomer H4
active metabolite with 900 mg reaches levels identical to
those measured with 300 mg in wt/*2 patients but does
not translate into a similar degree of platelet inhibition
CYP2C19*2 genotype
wt/wt wt/*2 *2/*2 wt/wt wt/*2 *2/*2
0
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Figure 3. Relative Change in ADP-Induced RPA According to
CYP2C19*2 and Clopidogrel LDs
Results are mean  SEM. LD  loading dose; RPA  residual platelet
aggregation.
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400measured either with LTA or the POC VN-P2Y12 assay.
his disconnect between PK and PD remains to be
lucidated, and could possibly be related to other un-
nown active metabolites via the CYP2C19-dependent
athway. This may explain also why low isomer H4 levels
eakly predict the antiplatelet effect irrespective of the
D assay (21). It should be acknowledged that the
orrelation between PK and PD responses does not reflect the
ssociation in a single population but rather reflects the
ffect of CYP2C19*2 carriage.
Study limitations. First, 80% of our study population were
white patients, so these results might be relevant to only
whites although the effects of CYP2C19 reduced-function
alleles on platelet inhibition with clopidogrel appear to be
CYP2C19*2 genotype
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Figure 4. Pharmacokinetic Response According to CYP2C19*2 and
Clopidogrel LDs
Results are mean  SEM. AUC  area under the plasma concentration time
curve from administration of the LD to 6 h; LD  loading dose.
Table 4. Clopidogrel Active Metabolite Isomer H4 Exposure According to P
Clopidogrel Pre-Treated Patients
(n  86)
wt/wt
(n  52)
300-mg post-loading AUC0-6 19.60 11.99
900-mg post-loading AUC0-6 41.62 26.35
Clopidogrel Naive Patients
(n  20)
wt/wt
(n  6)
300-mg post-loading AUC0-6 20.24 11.85
900-mg post-loading AUC0-6 35.44 19.22
p for interaction between pre-treatment status and CYP2C19 2 carriage was nonsignificant for AUCAUC0-6 area under the plasma concentration time curve from administration of the LD to 6 h (ng · h/mconsistent irrespective of ethnicity. Second, whether our
findings obtained in a young post-MI population can be
extrapolated to elderly patients with comorbidities, where
clopidogrel has more modest efficacy, remains to be estab-
lished. Third, whether a double MD of clopidogrel (150
mg), a dose that leads to significantly increased platelet
inhibition and decreased rate of HOPR but with no
established clinical benefit (6), may overcome the effect of
the *2 allele is unlikely, given the lack of effect of the
300-mg LD and recent findings of the ACCEL-DOUBLE
(Accelerated Platelet Inhibition by a Double Dose of
Clopidogrel According to Gene Polymorphism) trial (22).
A loading dose higher than 900 mg was not evaluated, given
our study design and prior results of the RELOAD (Reload
with Clopidogrel Before Coronary Angioplasty in Subjects
Treated Long Term with Dual Antiplatelet Therapy) study
showing no significant difference in platelet inhibition
between 300- and 600-mg reloading strategies in patients
on a MD of clopidogrel (2). In addition, LDs higher than
900 mg have a very modest effect on clopidogrel response in
*2/*2 carriers (23). The number of homozygous carriers is
low and could not be increased in this genotype enrichment
study design, and this may account for the different distri-
bution of baseline characteristics through the genotype
groups. Sample size calculation was performed irrespective
of the allele carriage status as opposed to statistical analyses
that were performed ignoring the matching process by
randomized tests for pragmatic reason given the recent
FDA warning on the CYP2C19*2 carriage status. Finally,
valuations of clinical outcome and of hyper response were
mitted, given the limited study population, and would
eserve further evaluation.
onclusions
The CLOVIS-2 investigation answers many of the con-
cerns raised by the FDA (10) and may help interpreting the
atment Status
Carriers
p Value
wt/2
(n  31)
2/2
(n  3)
14.56 9.34 8.71 2.17 0.02
31.73 21.69 18.09 6.80 0.03
Carriers
p Value
wt/2
(n  10)
2/2
(n  4)
16.26 8.23 10.87 3.29 0.53
35.64 26.81 14.17 3.96 0.06
ained after both LDs (p 0.98 for 300-mg LD; p 0.78 for 900-mg LD).re-Tre
0-6 obtl); LD loading dose; wtwild type.
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401American College of Cardiology/American Heart Associa-
tion recommendations on pharmacogenetic testing to iden-
tify patients’ altered clopidogrel metabolism (20). A high
clopidogrel dose can overcome poor response to the drug in
heterozygous carriers of the CYP2C19*2 genetic variant but
not in homozygous carriers, who probably deserve alterna-
tive therapy. CLOVIS-2 results suggest a codominant effect
of this loss-of-function allele and that genotyping of
thienopyridine-eligible patients may help individualize an-
tiplatelet therapy, something being tested now in prospec-
tive studies (Genotyping Infarct Patients to Adjust and
Normalize Thienopyridine Treatment [NCT01134380]; Ge-
notype Guided Comparison of Clopidogrel and Prasugrel
Outcomes study [NCT00995514)]; and TARGET-PCI
[Thrombocyte Activity Reassessment and GEnoTyping for
Figure 5. Correlations Between PD and PK According to Clopidogrel LD
(A) 300-mg LD and (B) 900-mg LD. Carriage of the loss-of-function
CYP2C19*2 allele is indicated as follows: white, wt/wt; blue, wt/*2; and red,
2/*2). AUC0-6 are reported on a logarithmic scale. R
2  0.20 for 300-mg
LD and 0.23 for 900-mg LD (p  0.0001 for both curves). Abbreviations as
in Figures 1, 3, and 4.PCI] NCT01177592)).Acknowledgments
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